Page 6 - Bharat Biotech

DCGI accords conditional market approval for Covaxin and Covishield

Firms will need to submit data of overseas ongoing clinical trials of their vaccines every 6 months

Neglected infectious diseases may be tomorrow's pandemic: Bharat Bio chief

Bharat Biotech International Limited Chairman Dr Krishna Ella on Monday said today's neglected infectious diseases could be tomorrow's global pandemic

'Hearing that 15-18 age group being given vaccine other than Covaxin'

: Bharat Biotech on Tuesday said it is receiving several reports that children in the age group 15 to 18 are being administered COVID-19 vaccine other than Covaxin. Requesting the health workers to be vigilant and ensure that only Covaxin is administered to that particular age group, Bharat Biotech in a twitter post said its vaccine is the only approved COVID-19 jab to be administered to children in the age group between 15 and 18. "We have received several additional reports of individuals in the 15-18 year age group being administered unapproved COVID-19 vaccines," the company said. Covaxin received approval based on thorough clinical trial evaluation for safety and immunogenicity in the 2-18 years age group. Currently it is the only COVID-19 vaccine in India approved for children, it added.

No full marketing authorisation yet for Covishield and Covaxin vaccines

Review process to continue, experts studying data submitted

Bharat Biotech seeks full marketing approval from DCGI for Covaxin

The company, however, is yet to submit the full follow up data of clinical trila of Covaxin to DCGI, a source said

Covaxin booster neutralises both Omicron and Delta variants: Bharat Biotech

'More than 90% of all individuals boosted with Covaxin showed neutralising antibodies,' says Hyderabad-based Bharat Biotech

Covaxin's makers could earn Rs 7,300 cr by vaccinating children

With a booster dose, the market of 12-18-year-olds represents a revenue pool as much as Rs 11,500 cr

Covaxin booster dose may give long-term immunity: Bharat Biotech

90% of recipients had a detectable neutralising antibody response against the wild-type strain (6 months after the second dose), the Hyderabad-based vaccine maker said

Bharat Biotech gets approval to test nasal Covid-19 shot as booster: Report

The vaccine maker submitted the late-stage trial application to the DCGI in December, adding that an intranasal vaccine as a booster dose will be easier to administer in mass vaccination campaigns

Covid LIVE: Maharashtra sees 18,466 new cases; Omicron tally reaches 653

The number of active cases are 66,308

SEC to hold meeting on Bharat Biotech's Nasal vaccine booster dose

SEC to hold meeting on Bharat Biotech's Nasal vaccine booster dose

Bharat Biotech starts re-labelling old stock after shelf life extension

After receiving the order from the Central Drugs Standard Control Organisation (CDSCO), the company started lifting unused stock from hospitals to re-label the shelf life from 9 months to 12 months

Covid-19: India supplies 500,000 more Covaxin doses to Afghanistan

Bharat Biotech on Monday informed that India has supplied another batch of humanitarian assistance consisting of 5,00,000 doses of COVID-19 vaccine, Covaxin to Afghanistan.Taking to Twitter, Bharat Biotech said, "Today, India supplied the next batch of humanitarian assistance consisting of 5,00,000 doses of COVID vaccine (COVAXIN) to Afghanistan. The same was handed over to Indira Gandhi Hospital, Kabul."It also informed that another batch of additional 5,00,000 doses would be supplied in the coming weeks.The last batch of humanitarian assistance consisting of 5,00,000 doses of Covaxin was supplied to Afghanistan on January 1.India has committed to provide to Afghan people humanitarian assistance consisting of food grains, one million doses of COVID-19 vaccine and essential life-saving drugs.Earlier last month, India delivered 1.6 tons of medical assistance to Afghanistan through the World Health Organization (WHO).The Taliban took over control of Kabul on August 15 and following this

Covaxin is safe for 2-18 age group in phase 2, 3 trials: Bharat Biotech

A total of 374 subjects reported either mild or moderate severity symptoms, with 78.6% getting resolved within a day, says Hyderabad-based vaccine maker

Covaxin found to be safe for children in phase 2, 3 trials: Bharat Biotech

The clinical trials conducted on the paediatric population between June-September 2021 have shown robust safety, reactogenicity, and immunogenicity, says Hyderabad-based firm

Vaccine makers bet global demand, boosters will drive growth next year

Domestic demand had fallen after cases began to decline. Omicron surge may reverse the trend

Bharat Biotech targets one billion doses of intranasal vaccine annually

The Hyderabad-based vaccine maker has already approached the Drug Controller General of India (DCGI) for approval to conduct phase-III trials of its intranasal vaccine

LIVE: Maharashtra sees 26 more cases of Omicron; night curfew in Kerala

Telangana reports 12 new Omicron cases in the last 24 hours

Bharat Biotech eyes 1 billion doses of nasal Covid-19 vaccine in 2022

Looks for global partners to produce and distribute vaccine - BBV154

Bharat Biotech seeks approval for Phase 3 trials of intranasal vaccine

Bharat Biotech has sought the approval of the Drug Controller General of India (DCGI) to conduct Phase 3 trials of its Covid-19 intranasal vaccine